Shanghai Haoyuan Chemexpress Co.Ltd(688131) ( Shanghai Haoyuan Chemexpress Co.Ltd(688131) . SH) announced on April 22 that in 2021, the company realized an operating revenue of 969 million yuan, an increase of 52.61% year-on-year; The net profit attributable to the shareholders of the listed company was 191 million yuan, with a year-on-year increase of 48.70%. The company plans to distribute a cash dividend of 5.3 yuan (including tax) to all shareholders for every 10 shares, and convert the capital reserve into 4 shares for every 10 shares.
Shanghai Haoyuan Chemexpress Co.Ltd(688131) is a platform high-tech enterprise focusing on the R & D service and industrial application of small molecule drugs. Its main business includes the R & D of molecular blocks and tool compounds in the field of small molecule drug discovery, as well as the process development and production technology improvement of small molecule drug APIs and intermediates, Provide global pharmaceutical enterprises and scientific research institutions with relevant products and technical services from drug discovery to large-scale production of APIs and pharmaceutical intermediates.
From the perspective of business structure, the company’s main operating revenue comes from the research and experimental development industry, which achieved an operating revenue of 962 million yuan during the period, with a year-on-year increase of 52.50%.
In terms of products, the molecular block and tool compound business realized an operating revenue of 545 million yuan, a year-on-year increase of 57.59%, of which the product sales realized an operating revenue of 478 million yuan, a year-on-year increase of 50.88%, and the technical service realized an operating revenue of 666351 million yuan, a year-on-year increase of 131.46%; The API and intermediate business realized an operating revenue of 417 million yuan, a year-on-year increase of 46.32%, of which the product sales realized an operating revenue of 345 million yuan, a year-on-year increase of 26.59%, and the technical services realized an operating revenue of 721112 million yuan, a year-on-year increase of 475.86%. Among them, the technical service business grew rapidly.
The company said that during the reporting period, the company’s performance growth was mainly due to the strong demand of cro and cdmo industries, the enhancement of the company’s R & D service capacity, the acceleration of the expansion of the product line available for tool compounds and molecular blocks, and the rapid expansion of the service capacity of the R & D market. The company continues to pay attention to the quality of products and services, and the brand awareness continues to improve. The substantial increase in orders during the reporting period has led to an increase in operating revenue and operating costs.
In terms of operating costs, the operating costs of the research and experimental development industry were 440 million yuan, a year-on-year increase of 61.63%. In terms of products, the operating cost of molecular blocks and tool compounds was 173 million yuan, a year-on-year increase of 68.09%; The operating cost of APIs and intermediates was 267 million yuan, a year-on-year increase of 57.71%. From the cost analysis table, the cost of research and experimental development industry is mainly composed of direct materials, direct labor, manufacturing expenses and entrusted processing expenses. Among them, direct materials amounted to 269 million yuan, a year-on-year increase of 56.38%, accounting for 61.15% of the total cost. The company said that it was mainly due to the rapid growth of the company’s business scale in the current period, resulting in a corresponding increase in operating costs.
In terms of period expenses, during the reporting period, the major changes are management expenses and R & D expenses. The management fee was 114 million yuan, with a year-on-year increase of 73.16%, mainly due to the expansion of personnel and the optimization of salary performance structure in order to improve management functions and operation capacity with the rapid expansion of the company’s business scale; The company’s office space increases, and the corresponding rental fee and decoration amortization fee increase; The R & D expenditure was 103 million yuan, with a year-on-year increase of 59.65%, mainly due to the company’s increasing R & D investment, adding R & D personnel and adjusting the salary performance of R & D personnel, as well as the increase in outsourcing R & D expenses due to the increase in the number of products with business expansion.
In terms of R & D, the company has always adhered to innovative R & D as the core driving force. Over the years, the company has continuously strengthened independent innovation R & D and maintained high R & D investment. During the reporting period, the company invested 103 million yuan in R & D, an increase of 59.65% over the same period of the previous year, and the R & D investment accounted for 10.67% of the operating revenue. As of December 31, 2021, the area of R & D office space of the group company has increased to more than 60000 square meters, of which the R & D office space in Shanghai has expanded to more than 32000 square meters, with a good R & D environment. In recent years, the company has successively invested in the upgrading construction project of Shanghai Haoyuan Chemexpress Co.Ltd(688131) Shanghai R & D center, the construction project of Anhui Haoyuan biomedical R & D center and Anhui Leyan company to promote the upgrading of the company’s R & D capacity. By the end of the reporting period, the above projects had been officially put into operation. Among them, Anhui Haoyuan biomedical R & D center, located in Ningma science and Technology Innovation Park, Cihu high tech Zone, Ma’anshan, has completed the construction of microbiological laboratory, safety assessment engineering technology research laboratory and high activity kg GMP laboratory. Among them, the analysis and testing center has provided detection and analysis for more than 20000 times, completed the R & D and production of more than 40 projects, and successfully passed the CNAs on-site review in April 2022. During the reporting period, based on the existing R & D centers, the company invested and built new R & D centers in Hefei, Yantai and Shanghai respectively.
During the reporting period, the company and its subsidiaries added 37 new applications for intellectual property projects, including 18 invention patents; There are 28 new intellectual property projects, including 7 invention patents. As of December 31, 2021, the company has obtained 154 intellectual property projects, including 44 invention patents, 40 utility model patents, 4 design patents and 66 software copyrights.
During the reporting period, the funds raised by the company were used for Shanghai Haoyuan Chemexpress Co.Ltd(688131) shanghai R & D center upgrading project, Anhui Haoyuan biomedical R & D center construction project, Anhui Haoyuan 121095 tons of pharmaceutical raw materials and intermediates construction project (phase I) and supplementary working capital. During the reporting period, the company used 289 million yuan of over raised funds for industrial expansion and investment acquisition to further strengthen independent R & D capacity, improve production capacity construction and expand product pipelines, including the acquisition and capital increase of Hefei ouchuang gene Biotechnology Co., Ltd. and the construction of pharmaceutical R & D and biological reagent R & D industrialization base project (phase I); Invest in the establishment of Yantai Haoyuan Biomedical Technology Co., Ltd., a wholly-owned subsidiary, and build a new drug creation and R & D service base project (phase I); Invest in the construction of Shanghai Haoyuan Chemexpress Co.Ltd(688131) new drug creation service laboratory construction project (phase I). In the future, with the help of the power of the capital market, the company will accelerate the agglomeration of innovation resources, vigorously develop various businesses of the company, further improve its core competitiveness and achieve high-quality development.
Shanghai Haoyuan Chemexpress Co.Ltd(688131) said that the company would further consolidate its position in the field of small molecule drug research and development services; Accelerate the construction of core technology platform and extend to the field of preparations; Continuously improve infrastructure construction and capacity expansion; Achieve brand upgrading and promote market expansion at home and abroad.
